Navigation Links
Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
Date:8/18/2009

Neurobiology, Biogen Idec. The rapid progression of this antibody is the result of a very effective joint collaboration, which capitalized on Neurimmunes novel RTM approach and our proven expertise in neuroscience and the development of therapeutic antibodies.

Alzheimers disease is the most prevalent age-related neurodegenerative disease affecting more than 15 million patients worldwide. There are currently no treatments approved to slow or stop the progression of the disease. Patients with Alzheimers disease experience the progressive loss of cognitive functions, particularly those related to memory, followed by death eight to 15 years after a progressive decline in their disease. The pathology of Alzheimers disease is characterized by distinctive features, including the deposition of Abeta in the form of senile plaques and the loss of specific neuronal populations in the brain.


About Neurimmune Therapeutics AG - www.neurimmune.com
Neurimmune Therapeutics AG is a Swiss biotechnology company dedicated to the identification of novel therapeutics for the treatment of human diseases with a focus on neurodegenerative disorders such as Alzheimers disease. Based on novel scientific concepts developed at the University of Zurich, Neurimmune Therapeutics has established a unique technology platform RTM (Reverse Translational Medicine) that supports Neurimmune Therapeutics translational research-focused drug discovery programs.

Neurimmune Therapeutics business strategy focuses on the discovery and development of human-derived antibodies through RTM at an early stage of the pharmaceutical value chain and partnering product candidates targeting significant markets and unmet medical needs with leading biopharmaceutical companies for later-stage development and marketing.

For further information please contact:
Michael Salzma
'/>"/>
b3c newswire

0

GOOD

Page: 1 2 3

Related biology news :

1. Amarna Therapeutics B.V. and TNO announce SVac research and development partnership
2. Continuous glucose monitoring technology -- special issue of Diabetes Technology and Therapeutics
3. NIH announces new program to develop therapeutics for rare and neglected diseases
4. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
5. Tufts University professor receives IADR Pharmacology/Therapeutics/Toxicology Award
6. Acorda Therapeutics submits new drug application for Fampridine-SR in multiple sclerosis
7. A novel target for therapeutics against Staph infection
8. Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration
9. Growing fuel and medicine: Advancing biofuels and plant-produced therapeutics
10. Sirtris review of sirtuin therapeutics for diseases of aging in Nature Reviews Drug Discovery
11. Media invitation: 20th EORTC-NCI-ACR Symposium on Molecular Targets and Cancer Therapeutics

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...ed in the November 2009 issue of the journal GENE... how a family of genes (1-aminocyclopropane-1-carb...r production of ethylene. This gas affects many as...ays the foundation for future genetic manipulation... survive and thrive in difficult terrain, increase...
(Date:11/20/2009)...versity of Oklahoma researchers were sequencing th...me project. Today, the OU Advanced Center for Ge...l effort to sequence the tomato genome with a $7.5...ndation for plant genomics. , "The tomato has t... tomato and crop yields will improve quality of li...
(Date:11/20/2009)...gin of biological molecules like RNA and DNA is ho...rom simple precursors. Now, in a study appearing i...structed one of the earliest evolutionary steps ye...ubunits using nothing but warm water. , Many re...ological molecules present, before DNA and protein...
Breaking Biology News(10 mins):It's a gas: New discovery may lead to heartier, high-yielding plants 2NSF awards $7.5M grant to University of Oklahoma for plant genomics 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 1Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 2Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 3Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease 4730 4New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 1New Research Shows 3A Neurofeedback is an Evidence Based Treatment for ADHD 4729 2Study demonstrates the anti inflammatory properties of pine bark extract 51856 1Study demonstrates the anti inflammatory properties of pine bark extract 51856 2
...Glynn, a professor at the University of Miamis Ros...as been selected to receive the 2007-2008 Provosts...s extraordinary research and scholarly pursuits, a... continued research support. , This marks the sec... first introduced in 1996, will receive this honor...
...trogen runoff from urban and agriculture land-use ... processes for reducing this pollutant before it e... nationwide team of 31 ecologists, including two f...ems Center. , The findings, published in the Ma... of 72 streams in 8 regions across the U.S. and Pu...
...one of the worlds most endangered speciesa North I...al Zoo Bird House. Keepers had been incubating the...tion by the chicks father, carefully monitoring it...ick starts to break through the shell. The chick r... specially designed brooding box. , The box will...
Other Biology News:UM coral scientist Peter Glynn wins award for scholarly activity 2Increasing nitrogen pollution overwhelms filtering capability of streams 2Rare North Island brown kiwi hatches at the Smithsonian's National Zoo 2
(Date:11/20/2009)...ries have an opportunity to take the lead in two s...niversity of Valencia (UV), working together with ...e fabric of the Spanish biotechnology industry. Th...ors have more clout than those in English-speaking...nd plants has been overlooked by the leading count...
(Date:11/20/2009)... Cell Therapeutics, Inc. ...the Ninth Circuit Court of Appeals reversed a U.S.... allowed to pursue all of its claims against The L...ourt for trial. CTI filed a complaint against The...t consultant for CTI,s product TRISENOX, in 2007 s...
(Date:11/19/2009)...ewswire-FirstCall/ -- Omeros Corporation (Nasdaq: ...s for the third quarter ended September 30, 2009. ...ros reported a net loss of $3.9 million, or $1.34 ...on, or $2.54 per share, for the same period in 200...he Company reported a net loss of $15.5 million, o...
(Date:11/19/2009)...WALTHAM, Mass., Nov. 19 Arlington ...d that the leading driver of antibiotic selection ...m activity against gram-positive and gram-negative...an cause nosocomial pneumonia, surveyed European p...ts that provide appropriate coverage against commo...
Breaking Biology Technology:Spanish biotechnology should focus on food and plant sectors to be more competitive 2Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3
... Inc., a subsidiary of,Eisai Corporation of North ...ulti-centered Phase II study of its MORAb-009 mono...aluate MORAb-009, plus the chemotherapy drugs,peme...for patients with,mesothelioma. , The primary ...f MORAb-009,as combination therapy with the curren...
...ll/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: A...new Senior Secured Term Loan and Revolving Credit ...ranger, administrative agent and lender for both t...financing includes a delayed draw secured term loa...olving credit facility with a borrowing base deriv...
... the California Institute for Regenerative Medicin... Stemedica Cell Technologies, Inc. ("Stemedic...;D lab and corporate headquarters. , ...9 -- Leadership of the California Institute for Re... two part visit to Stemedica Cell Technologies, In...
Other Biology Technology:Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 2Morphotek(R), Inc. Announces Initiation of MORAb-009 Phase II Study in First- Line Treatment of Mesothelioma 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 2Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 3Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities 4CIRM Completes Briefing Visit to Stemedica Cell Technologies 2CIRM Completes Briefing Visit to Stemedica Cell Technologies 3
Experion RNA StdSens Chips, 10 from Bio-Rad
MiniMACS Separation Unit from Miltenyi Biotec
Experion RNA HighSens Chips, 10 from Bio-Rad
...activated with carbonyl diimidazole chemistry that...e PS10 array contains the same binding chemistry a...hobic barrier coating. These arrays are 8 spot chi...ith one column of a standard 96-well microplate (9...
Biology Products: